KR20220074913A - S1p1 수용체와 관련된 상태를 치료하는 방법 - Google Patents
S1p1 수용체와 관련된 상태를 치료하는 방법 Download PDFInfo
- Publication number
- KR20220074913A KR20220074913A KR1020227014194A KR20227014194A KR20220074913A KR 20220074913 A KR20220074913 A KR 20220074913A KR 1020227014194 A KR1020227014194 A KR 1020227014194A KR 20227014194 A KR20227014194 A KR 20227014194A KR 20220074913 A KR20220074913 A KR 20220074913A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- disease
- administered
- treatment
- induction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962909113P | 2019-10-01 | 2019-10-01 | |
| US62/909,113 | 2019-10-01 | ||
| PCT/US2020/053642 WO2021067506A1 (en) | 2019-10-01 | 2020-09-30 | Methods of treating conditions related to the s1p1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220074913A true KR20220074913A (ko) | 2022-06-03 |
Family
ID=75337529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227014194A Withdrawn KR20220074913A (ko) | 2019-10-01 | 2020-09-30 | S1p1 수용체와 관련된 상태를 치료하는 방법 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220347158A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4037678A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022550458A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220074913A (cg-RX-API-DMAC7.html) |
| CN (2) | CN119280227A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020360413A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022005999A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156182A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL291654A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022003982A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202114656A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021067506A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023135506A1 (en) | 2022-01-13 | 2023-07-20 | Arena Pharmaceuticals, Inc. | Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104311472B9 (zh) * | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| EP2528894A1 (en) * | 2010-01-27 | 2012-12-05 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CA3002540C (en) * | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| JP6838744B2 (ja) * | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
| KR20190113955A (ko) * | 2017-02-16 | 2019-10-08 | 아레나 파마슈티칼스, 인크. | 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법 |
-
2020
- 2020-09-30 JP JP2022520471A patent/JP2022550458A/ja active Pending
- 2020-09-30 US US17/765,619 patent/US20220347158A1/en not_active Abandoned
- 2020-09-30 EP EP20873256.0A patent/EP4037678A4/en not_active Withdrawn
- 2020-09-30 CN CN202411419528.2A patent/CN119280227A/zh active Pending
- 2020-09-30 KR KR1020227014194A patent/KR20220074913A/ko not_active Withdrawn
- 2020-09-30 BR BR112022005999A patent/BR112022005999A2/pt not_active Application Discontinuation
- 2020-09-30 MX MX2022003982A patent/MX2022003982A/es unknown
- 2020-09-30 CA CA3156182A patent/CA3156182A1/en active Pending
- 2020-09-30 CN CN202080076189.6A patent/CN115038438A/zh active Pending
- 2020-09-30 WO PCT/US2020/053642 patent/WO2021067506A1/en not_active Ceased
- 2020-09-30 TW TW109134240A patent/TW202114656A/zh unknown
- 2020-09-30 AU AU2020360413A patent/AU2020360413A1/en not_active Abandoned
-
2022
- 2022-03-23 IL IL291654A patent/IL291654A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220347158A1 (en) | 2022-11-03 |
| MX2022003982A (es) | 2022-07-12 |
| WO2021067506A1 (en) | 2021-04-08 |
| JP2022550458A (ja) | 2022-12-01 |
| TW202114656A (zh) | 2021-04-16 |
| AU2020360413A1 (en) | 2022-04-14 |
| CA3156182A1 (en) | 2021-04-08 |
| AU2020360413A8 (en) | 2022-04-21 |
| CN119280227A (zh) | 2025-01-10 |
| EP4037678A4 (en) | 2023-11-29 |
| CN115038438A (zh) | 2022-09-09 |
| EP4037678A1 (en) | 2022-08-10 |
| IL291654A (en) | 2022-05-01 |
| BR112022005999A2 (pt) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3908276B1 (en) | Methods of treating conditions related to the s1p1 receptor | |
| JP6580053B2 (ja) | 潰瘍性大腸炎の治療用医薬組成物 | |
| JP2017200926A (ja) | 第一選択の抗TNEα療法に失敗したクローン病患者を治療するためのラキニモドの使用 | |
| JP2022536623A (ja) | 肺動脈性肺高血圧症の治療方法 | |
| JP2022511788A (ja) | S1p1受容体に関連する状態を治療する方法 | |
| WO2022099150A1 (en) | Methods of treating conditions related to the s1p1 receptor | |
| WO2021067506A1 (en) | Methods of treating conditions related to the s1p1 receptor | |
| WO2021163355A1 (en) | Formulations and methods of treating conditions related to the s1p1 receptor | |
| US20240299318A1 (en) | Amiselimod for preventing, treating or ameliorating ulcerative colitis | |
| RU2821032C1 (ru) | Способы лечения заболеваний, связанных с рецептором s1p1 | |
| TWI855501B (zh) | 治療方法 | |
| HK40063670B (en) | Methods of treating conditions related to the s1p1 receptor | |
| HK40063670A (en) | Methods of treating conditions related to the s1p1 receptor | |
| HK40116740A (en) | Methods of treating conditions related to the s1p1 receptor | |
| WO2025134072A1 (en) | Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod | |
| WO2023214312A1 (en) | Methods of treating atopic dermatitis with etrasimod | |
| HK40109901A (en) | Etrasimod for use in treating s1p1 receptor-associated disorders in combination with hormone treatment | |
| HK40094222A (en) | Amiselimod for preventing, treating, or ameliorating ulcerative colitis | |
| AU2023203085A1 (en) | Methods of treating conditions related to the S1P1 receptor | |
| US20210128541A1 (en) | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |